These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Lack of effects of isosorbide-5-mononitrate on hepatic hemodynamics in HBsAg-positive cirrhosis. Tsai YT, Lee FY, Lin HC, Chang TT, Lay CS, Wang SS, Kong CW, Lee SD, Lo KJ. Hepatology; 1989 Sep; 10(3):283-7. PubMed ID: 2759546 [Abstract] [Full Text] [Related]
25. Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment. Merkel C, Sacerdoti D, Bolognesi M, Bombonato G, Gatta A. J Hepatol; 1998 Apr; 28(4):622-30. PubMed ID: 9566831 [Abstract] [Full Text] [Related]
26. Postprandial splanchnic haemodynamic changes in patients with liver cirrhosis and patent paraumbilical vein. Berzigotti A, Dapporto S, Angeloni L, Ramilli S, Bianchi G, Morelli MC, Magalotti D, Zoli M. Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1339-45. PubMed ID: 15618843 [Abstract] [Full Text] [Related]
27. Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial. Junquera F, López-Talavera JC, Mearin F, Saperas E, Videla S, Armengol JR, Esteban R, Malagelada JR. Gut; 2000 Jan; 46(1):127-32. PubMed ID: 10601068 [Abstract] [Full Text] [Related]
29. NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. Berzigotti A, Bellot P, De Gottardi A, Garcia-Pagan JC, Gagnon C, Spénard J, Bosch J. Am J Gastroenterol; 2010 May; 105(5):1094-101. PubMed ID: 19920806 [Abstract] [Full Text] [Related]
37. Efficacy of Terminalia arjuna in chronic stable angina: a double-blind, placebo-controlled, crossover study comparing Terminalia arjuna with isosorbide mononitrate. Bharani A, Ganguli A, Mathur LK, Jamra Y, Raman PG. Indian Heart J; 2002 Jun; 54(2):170-5. PubMed ID: 12086380 [Abstract] [Full Text] [Related]
38. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction. Moleda L, Trebicka J, Dietrich P, Gäbele E, Hellerbrand C, Straub RH, Sauerbruch T, Schoelmerich J, Wiest R. Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421 [Abstract] [Full Text] [Related]
39. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. García-Pagán JC, Feu F, Bosch J, Rodés J. Ann Intern Med; 1991 May 15; 114(10):869-73. PubMed ID: 2014947 [Abstract] [Full Text] [Related]
40. Evaluation of postprandial hyperemia in superior mesenteric artery and portal vein in healthy and cirrhotic humans: an operator-blind echo-Doppler study. Sabbá C, Ferraioli G, Genecin P, Colombato L, Buonamico P, Lerner E, Taylor KJ, Groszmann RJ. Hepatology; 1991 Apr 15; 13(4):714-8. PubMed ID: 2010166 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]